ME צמיחת רווחי EPS רבעונית 23andMe Inc.

23andMe Holding Co. has established a global network of genomic profiles, becoming a valuable partner for pharmaceutical developers. Business revenues are based on the sale of DNA kits and paid subscriptions for medical advice. The quarterly EPS change reflects profit dynamics, where the indicator value reaches 81.80. The massive archive of biodata forms a powerful defensive barrier, despite strict privacy controls.
פילוחים אנליטיים ודוחות נתונים של חברת 23andMe Holding Co. (ME)

Quarterly earnings per share (EPS) growth measures the trend of net income per share, determining the fundamental stability and margin of safety of a business for the long-term investor. By analyzing the quarterly EPS change, one can see how the critical liquidity deficit of 23andMe Holding Co. (ME) and the shift in its business model impact the company's ability to generate real income.